epocrates logo
epocrates logo
epocrates logo
  • 0

Journal Article Synopsis

GOLD

GOLD 2027: LAMAs now preferred for Group A COPD

November 20, 2026

card-image

Clinical takeaway: For patients in GOLD group A, start with a long-acting muscarinic antagonist (LAMA) and continue it if it helps breathlessness; use a short-acting bronchodilator if a LAMA is unavailable or unaffordable. For patients who continue to experience flares despite triple therapy, consider biologic treatment when blood eosinophils are at least 300 cells/μL, matching the agent to the patient’s clinical profile.

The 2027 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report introduces some of its most notable updates in years, with a stronger focus on earlier diagnosis, imaging-based assessment, multimorbidity, and personalized treatment strategies. The document also incorporates emerging evidence for biologic therapies in select patients with COPD.

A key theme throughout the update is that COPD often begins long before airflow obstruction appears on spirometry. GOLD refined definitions for early COPD, COPD in young individuals, and pre-COPD, and added a new framework identifying patients who have symptoms, CT abnormalities, impaired diffusion capacity, preserved ratio impaired spirometry (PRISm), or accelerated lung function decline but do not yet meet diagnostic spirometric criteria. These patients should be monitored rather than dismissed as “normal.”

The guideline also strengthens the case for active case-finding. GOLD now points to evidence that proactive identification of symptomatic at-risk individuals, coupled with treatment, can improve outcomes. The report even introduces a vision for future “universal spirometry,” comparing longitudinal lung-function tracking to pediatric growth charts.

Imaging receives a bigger role as well. GOLD now suggests considering a non-contrast chest CT with inspiratory and expiratory views at least once in all patients with COPD where available. CT can identify emphysema, small-airway disease, mucus plugging, bronchiectasis, interstitial lung abnormalities, and important comorbidities, potentially helping clinicians tailor therapy and identify candidates for targeted interventions.

Drug recommendations remain centered on bronchodilator-based therapy, but GOLD modifies initial treatment for Group A patients. Rather than recommending any bronchodilator, the report now specifically favors a long-acting muscarinic antagonist (LAMA) as initial therapy based on evidence for symptom improvement in early disease.

Perhaps the most clinically important pharmacologic addition is expanded guidance on biologics. For patients already receiving LABA/LAMA/ICS triple therapy who continue to experience exacerbations and have blood eosinophil counts ≥300 cells/µL, GOLD now recommends considering dupilumab in those with chronic bronchitis or mepolizumab regardless of chronic bronchitis status. The report also reviews emerging evidence for other biologics, including tozorakimab, though these agents have not yet been fully incorporated into treatment algorithms.

The update highlights a broader concept of disease activity, encouraging clinicians to pursue not only symptom control but also “disease stability,” defined as no exacerbations, no worsening symptoms, and no accelerated lung function decline.

A notable quote from GOLD leadership underscores the guideline’s message: “It is time for the world to take COPD seriously,” reflecting the report’s renewed emphasis on earlier recognition and intervention.

What’s changed

  • Initial Group A treatment changed to favor a LAMA.
  • Refined definitions of early COPD, pre-COPD, mild COPD, and COPD in young individuals.
  • New pre-COPD framework identifies at-risk patients before spirometric COPD develops.
  • Expanded recommendations supporting active COPD case-finding and earlier diagnosis.
  • New discussion of universal longitudinal spirometry as a future lung-health strategy.
  • Chest CT now recommended for consideration at least once in all COPD patients where available.
  • Updated vaccination guidance, including RSV vaccine recommendations and discussion of newer influenza vaccines.
  • New information on low-global-warming-propellant inhalers.
  • Expanded cardiovascular disease section with greater emphasis on cardiopulmonary risk after exacerbations.
  • Dupilumab and mepolizumab added as options for selected patients with eosinophilic COPD who continue to exacerbate despite triple therapy.
  • New chapters and figures covering artificial intelligence, pulmonary rehabilitation, integrated care, and multimorbidity management.

Source: Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2026 Nov 15) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2027 Report. GOLD Executive Summary and Full Report

learn more about epocrates plus

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information